Stabilisation of kidney function (halting GFR decline for ≥12 months) is documented in approximately 50–60% of treated cohorts in early-stage CKD (stages 2–3). Advanced CKD (stages 4–5) shows lower response rates (30–40%), likely because fibrotic burden and residual nephron mass constrain regenerative potential. Reversal of established scarring is rare; the primary benefit is slowing progression toward dialysis or transplantation.
Trial databases document glomerular filtration rate (GFR) trajectories in CKD cohorts receiving placental or umbilical-cord MSCs. Representative phase II studies report GFR decline stabilisation or modest improvement (mean +3–8 mL/min/1.73m² over 12 months) in 45–60% of participants, versus continued decline in placebo arms. Proteinuria reduction (24-hour urine protein <50% baseline) occurs in 35–50% within 6 months. Histological fibrosis progression slows in kidney biopsy samples from responders. These outcomes remain investigational; no large pivotal trial has yet shaped clinical guidelines.
Sunt un candidat? → · Chronic Kidney Disease: full overview → · Cost Boala Renală Cronică → · Cost →
Revizuit medical de echipa editorială a StemCellAtlas cu Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită